



*Working to improve your health*

01 May 2024

## **AFT Licenses Maxigesic® IV in Brazil.**

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces the licensing of Maxigesic IV, the intravenous form of its proprietary pain relief medicine, for Brazil, the largest pharma market in South America and the tenth largest pharma market in the world<sup>1</sup>.

AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “We are delighted to announce our partnership with Brazil’s Halex Istar, an established hospital injectables focused company. It is the ideal partner for this market, the most significant in Latin America and one of the most important markets globally.”

Tiago Salinas, CEO of Halex Istar, said: “We are similarly excited to be establishing this partnership with AFT Pharmaceuticals, to be exclusively responsible for distributing its Maxigesic IV [Paracetamol with Ibuprofen] in Brazil. This helps Halex Istar to further strengthen its commitment to provide, to the Brazilian hospital pharmaceutical sector, innovative products of excellence. The medicine also complements our current multimodal analgesia portfolio”.

AFT has now out-licensing or its own distribution arrangements for Maxigesic IV in eight of the top Pharma markets in the world: USA, Germany, France, Italy, UK (AFT Pharma UK Ltd), Canada (AFT Pharma Canada Ltd), Spain and now Brazil. Dr Atkinson said, “We are pleased on the Maxigesic IV progress with launches now in 36 countries around the globe”.

### **Footnote**

1. <https://www.statista.com/statistics/245473/market-share-of-the-leading-10-global-pharmaceutical-markets/>

*For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer.*

### **For more information:**

#### **Investors**

Dr Hartley Atkinson  
Managing Director  
AFT Pharmaceuticals

#### **Media**

Richard Inder  
The Project  
Tel: +64 21 645 643

Tel: +64 9488 0232

### **About AFT Pharmaceuticals**

AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs<sup>1</sup>. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website [www.aftpharm.com](http://www.aftpharm.com).

### **About Halex Istar**

Halex Istar is one of the most relevant pharmaceutical companies in Brazil focused on the hospital sector, building up a significant business over 50 years. Based on pioneering and developing (being also responsible for launching Paracetamol injectable in Brazil), Halex Istar also stands out for constant pursuit of innovation and improvement for its products offered in the entire Brazilian territory with an injectable ready-to-use portfolio (including therapeutic classes such as analgesics, antibiotics, anti-inflammatory agents, and others) and medical devices. [www.halexistar.com.br](http://www.halexistar.com.br)